There is no cure for long COVID. As of 2025, no drug has received FDA approval specifically for treating the condition, and no single therapy reliably eliminates it. That said, the picture is not hopeless. Most people do recover over time, several promising treatments are in clinical trials, and practical symptom management strategies can meaningfully improve quality of life.
Why a Cure Has Been So Hard to Find
Long COVID is not one disease. It involves at least four overlapping biological problems, which likely vary in importance from person to person. That makes finding a single cure extremely difficult.
The first suspect is viral persistence. Some people appear to harbor fragments of the virus, particularly spike protein, in organs like the liver, lymph nodes, and intestines long after the initial infection clears. These lingering viral proteins can damage blood vessel walls, trigger ongoing immune activation, and keep the body in a state of low-grade inflammation for months.
The second problem is immune dysregulation. In many long COVID patients, certain immune cells remain altered well after infection. T-cell populations shift in ways that resemble chronic autoimmune conditions, and some patients produce autoantibodies, immune proteins that mistakenly attack the body’s own tissues. These autoantibodies have been identified as a potential predictor of who develops long COVID in the first place.
The third mechanism involves inflammation in the brain. Patients with brain fog show signs of sustained activation of the brain’s resident immune cells, along with elevated inflammatory signaling molecules. These inflammatory signals interfere with the brain’s ability to form new connections, generate new neurons, and consolidate memories. They also affect dopamine levels, which helps explain the motivation problems and mental fatigue many people describe. Markers of this inflammation have been found in spinal fluid, confirming that the process is not just “in people’s heads” in the dismissive sense.
Because these mechanisms overlap and interact differently in each person, a treatment that works for someone whose primary issue is viral persistence may do nothing for someone whose symptoms stem mainly from autoimmunity. This is the core challenge researchers face.
What the Largest Trials Are Testing
The NIH’s RECOVER Initiative is the biggest coordinated effort to find effective treatments. It has launched multiple phase 2 clinical trials testing different approaches simultaneously, a design meant to identify what works more quickly than traditional one-at-a-time drug testing.
One major trial, called RECOVER-VITAL, is testing whether a longer course of the antiviral Paxlovid can improve symptoms by clearing any virus still hiding in the body. The standard five-day course used for acute COVID is too short, researchers believe, to reach viral reservoirs in tissues. A separate trial, RECOVER-NEURO, is testing interventions for brain fog and cognitive dysfunction, including a web-based brain training program, a goal management training program, and a device that delivers mild electrical stimulation to the brain at home. Additional trials are examining treatments for the sleep disruption that affects many long COVID patients, including excessive daytime sleepiness and insomnia.
These are still phase 2 trials, meaning they’re testing safety and effectiveness in relatively small groups of 100 to 300 participants. Even positive results would need further confirmation before leading to approved treatments.
Can Antivirals Prevent Long COVID?
There is some evidence that taking Paxlovid during acute COVID infection reduces the chance of developing long COVID afterward, at least for certain people. A large observational study of nearly 500,000 patients found that those treated with Paxlovid within five days of infection had a 12% lower risk of developing long COVID compared to untreated patients. That translated to about 3 fewer cases per 100 people.
The benefit was spread across multiple symptom types: neurological problems like brain fog and headaches, lung issues like shortness of breath, joint pain, fatigue, and even loss of taste and smell. However, this protective effect was only observed in higher-risk patients, those over 50 or with existing health conditions that made severe COVID more likely. For younger, lower-risk patients, the data showed no meaningful benefit.
This is an important distinction. Paxlovid during acute infection may lower risk for some, but it is not a treatment for long COVID that has already developed. Whether a longer course of the drug can help people who already have long COVID is exactly what the RECOVER-VITAL trial is designed to answer.
Blood Filtration and Other Experimental Claims
You may have seen claims that filtering the blood through a process called plasmapheresis can remove “microclots” and relieve long COVID symptoms. A Cochrane review, considered the gold standard for evaluating medical evidence, found this claim unsupported. The particles in question are not actually clots but a type of protein aggregate that also appears in healthy people and those with other diseases like diabetes. No clinical trials have tested plasmapheresis for long COVID, and the rationale for the treatment remains unproven. The review explicitly recommended that patients not undergo the procedure outside of a properly controlled trial, noting it carries real risks and significant cost.
How Most People Actually Recover
A large population-based study tracking patients for two years found that about 68% of people with long COVID reported continued, gradual recovery over time. Another 13.5% improved or fully recovered by the 24-month mark. At one year after infection, roughly 18.5% reported they had not recovered. By two years, that number dropped only slightly to 17.2%, suggesting that while most improvement happens in the first year, a subset of patients experience symptoms that persist well beyond that window.
These numbers mean the majority of people with long COVID do get better, but the timeline is often longer than anyone wants, and recovery frequently is not complete. Many people describe a pattern where symptoms improve, return, and improve again over months.
Managing Symptoms While You Wait
Without a cure, the most effective approach available right now is careful symptom management, and the single most important strategy is pacing. Pacing means staying within your body’s current energy limits rather than pushing through fatigue, then resting, then pushing again.
The approach rests on three core principles. First, identify your current physical and mental limits for daily activities and do not exceed them. This means prioritizing tasks, alternating periods of activity with rest, and breaking larger tasks into smaller pieces. Second, learn your personal triggers for symptom flare-ups, which researchers call post-exertional malaise. Common triggers include physical and mental exertion, emotional stress, standing for long periods, temperature extremes, strong sensory stimuli like bright lights or loud noise, and even certain foods. Third, plan your days around avoiding those triggers rather than reacting to crashes after they happen.
Notably, graded exercise therapy, the approach of progressively increasing physical activity, has been shown to be ineffective for post-viral fatigue conditions and can cause serious relapses. It has been removed from clinical guidelines for similar conditions. This is a critical point: the instinct to “exercise your way back to health” can genuinely make long COVID worse.
Over 200 Symptoms, One Diagnosis
Long COVID is formally defined as a chronic condition that begins within three months of a COVID-19 infection and lasts at least two to three months. Over 200 different symptoms have been reported. The most common include fatigue, muscle and joint pain, shortness of breath, headaches, difficulty thinking or concentrating, and changes in taste or smell. Sleep disruption, depression, and anxiety are also frequent. Symptoms can emerge, resolve, and return in unpredictable cycles over weeks and months.
A positive COVID test is not required for diagnosis. Your doctor can make the determination based on your health history, symptoms, and known or likely exposure. This matters because many people with long COVID were infected early in the pandemic before widespread testing was available, or had mild initial infections they never confirmed with a test.